Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC
Status:
Unknown status
Trial end date:
2020-09-20
Target enrollment:
Participant gender:
Summary
The study was to evaluate the safety, PFS and ORR of icotinib/dihydroaremisinin (DHA)-based
combination therapy in EGFR-mutated, advanced NSCLC patients who have gradually progressed
disease after first-line icotinib treatment.